Cancel

The Patient with Non-Small Cell Lung Cancer

The management of non-small cell lung cancer (NSCLC) has evolved in the past decade, as advances are made in diagnosis, characterization and treatment of the disease. Chemotherapy has seen refinements to make it more efficacious and less toxic, while targeted therapy has made its debut in this setting. This educational activity will discuss treatment options in patients with NSCLC.
Vindico Medical Education

The Patient with Non-Small Cell Lung Cancer

The management of non-small cell lung cancer (NSCLC) has evolved in the past decade, as advances are made in diagnosis, characterization and treatment of the disease. Chemotherapy has seen refinements to make it more efficacious and less toxic, while targeted therapy has made its debut in this setting. This educational activity will discuss treatment options in patients with NSCLC.
Vindico Medical Education

Case 2: 60-Year-Old Woman Following Induction Therapy for Active MM

Personalizing treatment regimens for multiple myeloma patients in both the frontline and salvage settings continues to pose a challenge for clinical oncologists, as newer therapeutic agents and combination treatments continue to expand the armamentarium. With this greater number of available agents comes the need for heightened attentiveness to identifying patients most likely to benefit from consolidation and maintenance therapies, effectively managing treatment-related toxicities, and select...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Case 1: Adult Woman With Elevated Protein

The rapidly increasing number of therapeutic options available for the management of multiple myeloma presents a significant challenge for hematologist-oncologists. Achieving optimal patient outcomes requires identifying the disease as early as possible and determining the best combination of agents for each patient based on a careful assessment of the biologic and genetic features of his or her disease. In Case 1, you will meet 58-year-old Donna Medford, who was referred to the Multiple My...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

38th Annual Intensive Review of Internal Medicine: The Harvard Medical School Board Review

Ace the ABIM Board Examinations with the 38th Annual Intensive Review of Internal Medicine: The Harvard Medical School Board Review. This course is specifically oriented to preparing you for the Board Examinations.  Topics include:  Nephrology Board Review, Acid-Base Board Review, Hematology Board Review, GI Board Review, Oncology Board Review, Cardiology Board Review, Women's Health Board Review, Pulmonary Board Review, Internal Medicine Board Review, Neurology Board Review, Endocrine Bo...
CMEInfo

World Lung Updates: Immunotherapy in NSCLC

Upon successful completion of this educational activity, participants should be better able to: Examine new evidence about the efficacy of investigational immunotherapeutic agents in NSCLC, as monotherapy and in combination with other agents. Review the latest information about the immunologic profiles and unique toxicities associated with immunotherapeutic agents being investigated for NSCLC.
Vindico Medical Education

Immunotherapy Updates 2015: FOCUS on NSCLC Monograph

Upon successful completion of this educational activity, participants should be better able to: Assess new evidence about the clinical utility of emerging immunotherapeutic agents in the treatment of non-small cell lung cancer. Examine the latest safety and quality-of-life data from clinical trials utilizing immunotherapies in non-small cell lung cancer to aid in increasing physician awareness about these novel approaches and enable incorporation of these strategies in future practice.
Vindico Medical Education

Updates in Melanoma 2015: Entering a New Therapeutic Era

The incidence of melanoma, an aggressive disease that accounts for approximately 75% of skin-cancer-related deaths, is continuing to increase worldwide. Historically, treatment options for patients with advanced-stage melanoma have been limited by modest response rates and failure to improve overall survival (typically less than 1 year). However, in recent years, the treatment landscape for metastatic melanoma was revolutionized with the approval of novel targeted therapies and immunotherapies...
Vindico Medical Education

Internal Medicine CME Online Bundle: Board Review - Journal Summaries - $500 Amazon.com Gift Card

The Internal Medicine CME Online Bundle features: • From CMEinfo and the experts at UCSF - Internal Medicine Board Certification and Recertification Review, an ABIM exam prep course • From Practical Reviews - A one-year subscription, including the FREE mobile app • A $500 Amazon.com gift card • Unbiased content to help you prep for the boards • Instant online access to key clinical updates Topics include: Pulmonary Medicine, Critical Care, Geriatrics, Gastroenterology, Infecti...
CMEInfo

Updates in Immunotherapy – Philadelphia 2015

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval of the programmed death-1 (PD-1) inhibitor pembrolizumab and the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) inhibitor ipilimumab for treatment of advanced melanoma, the approval of the PD-1 inhibitor nivolumab for treatment of advanced squamous non-small cell lung cancer (NSCLC), and the FDA Breakthrough Therapy Designation to pembrolizumab for the treatment of patien...
Vindico Medical Education

Immunotherapy Updates 2015: FOCUS on NSCLC

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers. Approximately 70% of patients with NSCLC present at locally advanced stages, which are associated with poor survival rates. Although the past decade has witnessed several breakthroughs in the diagnosis, treatment, and management of NSCLC, survival rates remained dismal. Immunotherapy is rapidly evolving into an effective treatment option for NSCLC. Checkp...
Vindico Medical Education

Emergency Medicine Hawaiian Islands Cruise

The purpose of this activity is to review the acute management of traumatic injuries, poisonings and other emergency conditions for physicians. Topics: •Remember that patient ..... using cognitive reasoning principles to avoid bouncebacks • CO poisoning •Marine trauma •Diagnoses at a glance •Toxicology •Hematology/Oncology emergencies •Syndromes you can't afford to miss •ECG Patterns that should stop and make you think •Ballistics and Firearm Wounds •Hot ...
Continuing Education, Inc

Tailored Therapies for Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical manifestations. The main clinical complication in MDS is morbidity due to cytopenias and the potential to progress into acute myeloid leukemia (AML). Unfortunately, approximately 30% of patients will eventually develop leukemia, and even in those who do not, prognosis is extremely poor. Prognosis is based on the International Prognostic Scoring System (IPSS) or the Revised International ...
Vindico Medical Education

MKSAP 17 Audio Companion: The American College of Physicians Program

The MKSAP 17 Audio Companion is made up of audio interviews with expert contributors from the country's leading medical facilities and teaching institutions. Listening to the MKSAP 17 Audio Companion helps to prepare you for ABIM certification or maintenance of certification. Topics include: Cardiovascular Medicine, Dermatology, Gastroenterology, Hepatology, Hematology, Oncology, Neurology, Rheumatology and the full range of internal medicine subjects.
CMEInfo

UCSF Internal Medicine Board Certification and Recertification Review

Succeed in the American Board of Internal Medicine Certification or Recertification Examination with the Internal Medicine Board Certification and Recertification Review from UCSF.  After the Introduction and Test Taking Tips, this course covers the full range of Internal Medicine topics likely to be covered on the exam, including:  Cardiology, Gastroenterology, Hospital Medicine, Infectious Disease, Rheumatology, Oncology, Neurology, Hematology, Nephrology, Endocrinology, Primary Care, Am...
CMEInfo

Hematopathology: A Comprehensive Review

Hematopathology: A Comprehensive Review should be most valuable to pathologists, pathologists-in-training, fellows in hematology and oncology and board certified hematologists/oncologists preparing for recertification. Areas covered include: • Hematopoietic Neoplasms • Disorders of Coagulation • Disorders of Red Blood Cells • Disorders of Lymph Nodes and Spleen • Molecular Diagnostics After completing Hematopathology: A Comprehensive Review, you will be able to: • Discuss t...
CMEInfo

The Brigham Board Review in Hematology

Topics covered by The Brigham Board Review in Hematology include:  Hematopoietic Stem Cell Transplantation, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndromes, Hodgkin's Lymphoma, Bone Marrow Failure, Hemophagocytic Syndromes, Sickle Cell Disease, Thalassemia and many others. After completing The Brigham Board Review in Hematology, you will be able to: • Apply current/recommended Hematology guidelines in clinical practice • Perform differential diagnosis of comple...
CMEInfo

The Brigham Board Review in Hematology and Oncology

Get ready for the ABIM exam in Hematology-Oncology by studying this Brigham Board Review in Hematology and Oncology. Topics covered by the Brigham Board Review in Hematology and Oncology include: Molecular Genetics of Cancer, Cancer Drug Development, Hematopoietic Stem Cell Transplantation, Acute Leukemias, Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin's Lymphoma, B Cell Malignancies, Mesothelioma, Thyroid Cancer and dozens of others. After completing the Brigham Board Review in Hemat...
CMEInfo

The Oncologist: What keeps oncologists from addressing palliative care early on with incurable cancer patients? –an active stance seems to be key

Learning objectives 1. Discuss openly with patients issues and decisions regarding the last phases of their lives. 2. Use your own empathy as an important nonmedical factor in the decision process. Background. Sympathetic and frank communication about the terminal nature of advanced cancer is important to improve patients’ prognostic understanding and, thereby, to allow for adjustment of treatment intensity to realistic goals; however, decisions against aggressive treatments are often m...
Society For Translational Oncology

IFIs: Epidemiological Trends, Antifungal Resistance, and Why Antifungal Therapy Fails in Patients with Invasive Mold Infections

Target audience The enduring activity is intended for health care professionals, particularly physicians, clinical microbiologists, researchers, nurse, nurse practitioners and pharmacists, specializing in prevention and management of fungal infections. Learning objectives Upon completion of the educational activity, participants should be able to: -Discuss the role of prophylaxis therapy in patients with invasive fungal infections (IFIs) -Review the emerging data on breakthrough and rel...
AKH Inc. Advancing Knowledge in Healthcare

Drug Interactions with Chemotherapy

Activity Description Participants in this webinar will learn the reasons for patient nonadherence to oral chemotherapy regimens, and how adherence can be improved. Faculty will review the pharmacokinetics of oral oncolytic drugs, such as methotrexate and vincristine, and will use case studies to illustrate potentially significant interactions with other drugs or foods, and how they can be prevented or managed if they occur. Strategies for educating patients about potential drug interactions...
ProCE

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.